Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PMF, PPV-MF, or PET-MF.~* DIPSS risk category of intermediate-1, intermediate-2, or high.~* Treated with ruxolitinib for ≥ 3 months with a stable dose for at least the last 8 weeks prior to Day 1~* Palpable spleen of ≥ 5 cm below the left costal margin on physical examination at the screening visit.~* Active symptoms of MF at the screening visit, as demonstrated by the presence of a TSS of ≥ 10 using the Screening Symptom Form.~* Participants with an ECOG performance status score of 0, 1, or 2.~* Screening bone marrow biopsy specimen and pathology report(s) available that was obtained within the prior 2 months or willingness to undergo a bone marrow biopsy at screening/baseline; willingness to undergo bone marrow biopsy at Week 24 and every 24 weeks there after. Screening/baseline biopsy specimen must show diagnosis of MF.~* Life expectancy of at least 24 weeks.~* Willingness to avoid pregnancy or fathering children.~Exclusion Criteria:~* Prior therapy with any drug that inhibits PI3K (examples of drugs targeting this pathway include but are not limited to INCB040093, idelalisib, duvelisib, buparlisib, copanlisib, and umbralisib).~* Use of experimental drug therapy for MF or any other standard drug used for MF (whether for treatment of MF or another indication) with the exception of ruxolitinib, within 3 months of starting study drug, and/or lack of recovery from all toxicities from previous therapy (except ruxolitinib) to Grade 1 or better.~* Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications.~* Recent history of inadequate bone marrow reserve.~* Inadequate liver and renal function at screening.~* Active bacterial, fungal, parasitic, or viral infection that requires therapy.~* Active HBV or HCV infection that requires treatment or at risk for HBV reactivation.~* Known HIV infection.~* Uncontrolled, severe, or unstable cardiac disease that in the investigator's opinion may jeopardize the safety of the participant or compliance with the Protocol.~* Active invasive malignancy over the previous 2 years.~* Splenic irradiation within 6 months before receiving the first dose of study drug.~* Concurrent use of any prohibited medications.~* Active alcohol or drug addiction that would interfere with the ability to comply with the study requirements.~* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half lives(whichever is longer) before the first dose of study drug or anticipated during the study.~* Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.~* Currently breastfeeding or pregnant.~* Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.~* History of Grade 3 or 4 irAEs from prior immunotherapy.~* Receipt of any live vaccine within 30 days of the first dose of study drug~* Unwillingness to receive RBC transfusions to treat low hemoglobin levels.~* Known hypersensitivity or severe reaction to parsaclisib or ruxolitinib or excipients of parsaclisib/matching placebo or ruxolitinib formulations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A : ruxolitinib +parsaclisib (Type: EXPERIMENTAL): Participants will receive parsaclisib starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
- Group B : ruxolitinib + placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).